Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performan...
Mendias CL, Awan TM — Sports medicine (Auckland, N.Z.)
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, M...
Rahman OF, Lee SJ, Seeds WA — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples
Peptides with a molecular mass between 2 and 10 kDa that are prohibited in elite sports usually require dedicated sample preparation and mass spectrometric detection that commonly cannot be combined with other (lower molecular mass) substance...
Thomas A, Walpurgis K, Thevis M — Journal of mass spectrometry : JMS
Probing for peptidic drugs (2-10 kDa) in doping control blood samples
Bioactive peptides with a molecular mass between 2 and 10 kDa represent an important class of substances banned in elite sports, which has been recognized with an increasing number and variety of substances by anti-doping organizations. Also,...
Thomas A, Thilmany S, Hofmann A et al. — Analytical science advances
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples
The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should...
Cristea CD, Radu M, Toboc A et al. — Analytical biochemistry
In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides
Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness and accuracy. To counteract this effect, an internal standard (IS) is used; however, in most cas...
González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I et al. — Biomedical chromatography : BMC
Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis
A capillary electrophoresis method is proposed to analyze the four most well-known growth hormone-releasing hormone (GHRH) analogs that are misused by athletes. Dimethyl-β-cyclodextrin used as a chiral selector allowed, for the first time, t...
Otin J, Tran NT, Benoit A et al. — Electrophoresis
A potentially effective drug for patients with recurrent glioma: sermorelin
Treatment insensitivity is the main cause of glioma. This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data.
Chang Y, Huang R, Zhai Y et al. — Annals of translational medicine
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nan...
Coppieters G, Deventer K, Polet M et al. — Journal of pharmaceutical and biomedical analysis
Advances in the detection of growth hormone releasing hormone synthetic analogs
The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Although there is evidence of their use, based on admissions and intelligence, they do not appear to have...
Memdouh S, Gavrilović I, Ng K et al. — Drug testing and analysis
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Male hypogonadism is an increasingly prevalent clinical condition that affects patients' quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standar...
Sinha DK, Balasubramanian A, Tatem AJ et al. — Translational andrology and urology
Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe
Operation Pangea is an annual international week of action combating pharmaceutical crime. In this study, called Operation Resistance, we asked the national agencies in Europe to search for falsified antibiotics and biopharmaceutical injectables (...
Venhuis BJ, Keizers PH, Klausmann R et al. — Drug testing and analysis
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). The aim of the present study was to develop a method for the simultaneous detection of four different...
Knoop A, Thomas A, Fichant E et al. — Analytical and bioanalytical chemistry
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS
Bioactive peptides with an approximate molecular mass of 2-12 kDa are of considerable relevance in sports drug testing. Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include ...
Thomas A, Walpurgis K, Tretzel L et al. — Drug testing and analysis
Growth Hormone Releasing Hormone Analog Sermorelin: Clinical Applications and Pharmacology
Review of sermorelin as a GHRH analog for restoring pulsatile growth hormone secretion. Documented safety profile in adults with age-related GH decline. Does not suppress endogenous GH production, unlike exogenous GH.
Truthe take: Sermorelin is the reason we use GHRH analogs instead of injecting growth hormone directly. It restores the body's own pulsatile pattern. Safer, more physiologic, less regulatory risk.
Walker RF — Expert Opinion on Investigational Drugs
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion...
Prakash A, Goa KL — BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
PEGylation of growth hormone-releasing hormone (GRF) analogues
Synthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-44 (Figure 1). It maintains bioactivity in vitro and is almost equally effective in eli...
Esposito P, Barbero L, Caccia P et al. — Advanced drug delivery reviews